National Psoriasis Foundation

Clinical Trials

Find a trial

Reasons to participate

  • Access to new treatments not available on the market.
  • Access to free medication.
  • Compensation for participating (in some trials).
  • Satisifcation in helping advance medical research.

Factors to consider

It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

The purpose of this study is to determine the relationship between two types of cell signals (type I IFN and TNF) in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.

Condition: Psoriasis | Phase: Phase 4 | Minimum Age: 18 Years

Learn more »

This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for S

This study is being conducted to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis.

Condition: Psoriasis | Phase: Phase 2 | Minimum Age: 18 Years

Learn more »

DFD01 Spray vs. Comp01 Lotion HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

This study evaluates the potential of HPA suppression in adolescent patients with moderate to severe plaque psoriasis when using DFD01 Spray (twice daily for either 15 or 29 days) vs. Comp01 Lotion (twice daily for 15 days).

Condition: Plaque Psoriasis | Phase: Phase 3 | Minimum Age: 12 Years

Learn more »

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

The purpose of this study is to evaluate the efficacy of re-treatment with etanercept 50mg subcutaneous injections twice weekly for 12 weeks in subjects who have previously been treated etanercept and efficacy diminished.

Condition: Psoriasis | Phase: Phase 4 | Minimum Age: 18 Years

Learn more »

Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

This is a proof of concept, investigator blinded study to evaluate the efficacy and safety of a novel combination of a home narrow band ultraviolet B (NBUVB) lamp with an occlusive dressing in adult subjects with mild to moderate psoriasis vulgaris. Four interpatient arms will be used to compare the efficacy of combination of NBUVB with an occlusive dressing to the light alone and to dressing alone and no treatment. Ten patients will be enrolled in this 6 weeks study.

Condition: Psoriasis | Phase: N/A | Minimum Age: 18 Years

Learn more »

Get the latest research news and tips on managing your psoriasis and psoriatic arthritis.